+44 20 8123 2220
info@marketpublishers.com

# Non-Small Cell Lung Cancer (Nsclc) - Market Access, Reimbursement Outlook, Competitive Landscape, Epidemiology and Forecast Report - 2015 To 2030

https://marketpublishers.com/r/N3DCD4BC980EN.html
Date: December 2017
Pages: 172
Price: US$ 6,550.00 (Single User License)
ID: N3DCD4BC980EN

## Abstracts

Thelansis Knowledge Partners 'Non-Small Cell Lung Cancer (NSCLC)' - Market Access, Reimbursement Outlook, Competitive Landscapet, Epidemiology and Forecast Report – 2015 to 2030' report comprises of the Disease overview, classifications, stages or severity level, pathogenesis, identified and emerging biomarkers, pipeline assessment, competitive landscape, KOLs perspective, Market access - Country Specific Regulatory scenario
s, Patent landscape, reimbursement scenario; Public, Private, Medicare, Medicaid, Government, Private, Co-payment, Out of pocket, Epidemiology; Incidence, Prevalence, Mortality, and current therapy market share, Order of entry, patient share, Market uptake, Peak patient share, Disease burden, Annual cost of therapy, market forecast for USA, Germany, France, Italy, Spain, UK, Japan and China 2015 to 2030

Geographic Coverage

United States

EU5 (Germany, France, Italy, Spain and the United Kingdom)

Japan

China

Market estimation: 2015 – 2030

+44 20 8123 2220
info@marketpublishers.com

Report brief:

Epidemiology

This section provide the insights about historical and current patient pool (Incidence, Prevalence and mortality) and forecasted trend for 8 major markets (US, Germany, France, Italy, Spain, UK, Japan and China). The epidemiology research is one the key element of the report driven by meta-analysis, Systemic literature review and insights from KOL’s

Treatment Algorithm

The comprehensive details on country specific treatment and disease management for the patients with Non-Small Cell Lung Cancer (NSCLC) in the US, Europe, Japan, and China. Future treatment paradigm and KOL’s perspective (HCP’s, Payers and Researcher) are the key strength of the report

Competitive Landscapet

A thorough analysis of reported revenue, patient share and marketed trend for approved therapies however for pipeline assets we consider Phase I, Phase II and Phase III including their major milestones, study result, interim result, safety & efficacy data, key drivers, mechanism of action designation (Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review) geography level prioritization, asset level profile and probable launch date estimation

Market Outlook & Market Forecast

Historic, current and forecasted market trend (High, Base case, Low) of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better diagnosis of biomarkers. Key patient segment and market based on type, severity and stages of the disease. Disease burden, compliance rate, annual cost of therapy, reimbursement scenario, Patient share, Patient access

Market uptake and benchmarking

The market penetration for pipeline assets being derived on the basis of benchmarking the sales of launched assets specifically targeting the patient segment or overall indication or therapy area or country or region specific. Order of entry benchmark works

+44 20 8123 2220
info@marketpublishers.com

as a critical element for defining the uptake curve for the pipeline assets. Many drug utilization study are being benchmarked to arrive at the current patient share for marketed therapies as well as off-label products. Market events are the major key factors which applied to the forecast model to optimize the year on year revenue estimation

Regulatory scenario

Country specific healthcare structure, regulatory bodies, HTA bodies, approval process for diagnostic and therapies, and work flow

Patent landscape

Country specific patent filings for approved therapies as well as pipeline assets, formulation patent, process patent (FDA, EMA, EPO, Orange book, JPO; Japan Patent Office) and fillings

Reimbursement Scenario

Country specific reimbursement Scenario; Public, Private, Medicare, Medicaid, Government, Private, Co-payment, Out of pocket

Key Report highlights

- 4 years of historical epidemiology data Epidemiology; Incidence, Prevalence, Mortality
- 11 years of epidemiology and market projections
- Incidence/ Prevalence patient population
- Mortality, survival and diagnosed patient pool
- Treated patient pool
- Treatment guidelines
- Competitive landscape (Marketed therapies, Off-label therapies, Pipeline assessment, Phase – I, II, III)

+44 20 8123 2220
info@marketpublishers.com

Patient share

Country specific revenue share and trend

Market Opportunities assessment

Key market and product event analysis

Disease burden and annual cost of therapy

Regulatory scenario

Reimbursement Scenario

Patent landscape

HCP’s/ KOL’s perspective

Payer’s perspective

Analyst commentary Bergenbio Asa, Chiltern International Inc., Huya Bioscience International, Sciclone Pharmaceuticals, Emd Serono, Merck Kgaa, Incyte Corporation, Astrazeneca, Ono Pharmaceutical Co. Ltd, Bristol-Myers Squibb, Eli Lilly And Company, Armo Biosciences, Merck Sharp & Dohme Corp., Eisai Inc., Bristol-Myers Squibb, Ppd, Janssen Research & Development, Llc, Genentech, Inc., Eli Lilly And Company, Merck Sharp & Dohme Corp., Oncomed Pharmaceuticals, Inc., Celgene Corporation, Daiichi Sankyo, Inc., Betta Pharmaceuticals Co., Ltd., Abbvie, Syndax Pharmaceuticals, Celgene, Beigene, Clovis Oncology, Inc., Novartis Pharmaceuticals, Regeneron Pharmaceuticals, Sanofi, Turnstone Biologics, Inc., Eli Lilly And Company, Astrazeneca, Millennium Pharmaceuticals, Inc., Takeda, Biocad, Kyowa Kirin, Arrys Therapeutics, Cstone Pharmaceuticals, Biomarck Pharmaceuticals, Ltd., Janssen Research & Development, Llc, Astellas Pharma Inc, Mirati Therapeutics Inc., Allist Pharmaceuticals, Inc., Bavarian Nordic, Glaxosmithkline, Novocure Ltd., Jiangsu Hengrui Medicine Co., Ltd, Newlink

+44 20 8123 2220
info@marketpublishers.com

Genetics Corporation, Luye Pharma Group Ltd., Hangzhou Acea Pharmaceutical Research Co., Ltd., Samsung Bioepis Co., Ltd., Loxo Oncology

+44 20 8123 2220
info@marketpublishers.com

# Contents

+44 20 8123 2220
info@marketpublishers.com



## 3. EPIDEMIOLOGY



## 4. MARKET OUTLOOK

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com



## 5. COMPETITIVE LANDSCAPE

+44 20 8123 2220
info@marketpublishers.com



## 6. REGULATORY FRAMEWORK SCENARIO

+44 20 8123 2220
info@marketpublishers.com



## 7. CLINICAL TRIAL ASSESSMENT – CURRENT AND FUTURE PARADIGM

+44 20 8123 2220
info@marketpublishers.com



## 8. MARKET ACCESS



## 9. THELANSIS' COMMENTARY



## 10. REPORT METHODOLOGY



## 11. ABOUT THELANSIS

+44 20 8123 2220
info@marketpublishers.com

## I would like to order

Product name: Non-Small Cell Lung Cancer (Nsclc) - Market Access, Reimbursement Outlook, Competitive Landscape, Epidemiology and Forecast Report - 2015 To 2030

Product link: https://marketpublishers.com/r/N3DCD4BC980EN.html

Price: US$ 6,550.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/N3DCD4BC980EN.html

## To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

+44 20 8123 2220
info@marketpublishers.com